Dataset Information


PD-1 blockade enhances the vaccination-induced immune response in glioma.

ABSTRACT: DC vaccination with autologous tumor lysate has demonstrated promising results for the treatment of glioblastoma (GBM) in preclinical and clinical studies. While the vaccine appears capable of inducing T cell infiltration into tumors, the effectiveness of active vaccination in progressively growing tumors is less profound. In parallel, a number of studies have identified negative costimulatory pathways, such as programmed death 1/programmed death ligand 1 (PD-1/PD-L1), as relevant mediators of the intratumoral immune responses. Clinical responses to PD-1 pathway inhibition, however, have also been varied. To evaluate the relevance to established glioma, the effects of PD-1 blockade following DC vaccination were tested in intracranial (i.c.) glioma tumor- bearing mice. Treatment with both DC vaccination and PD-1 mAb blockade resulted in long-term survival, while neither agent alone induced a survival benefit in animals with larger, established tumors. This survival benefit was completely dependent on CD8(+) T cells. Additionally, DC vaccine plus PD-1 mAb blockade resulted in the upregulation of integrin homing and immunologic memory markers on tumor-infiltrating lymphocytes (TILs). In clinical samples, DC vaccination in GBM patients was associated with upregulation of PD-1 expression in vivo, while ex vivo blockade of PD-1 on freshly isolated TILs dramatically enhanced autologous tumor cell cytolysis. These findings strongly suggest that the PD-1/PD-L1 pathway plays an important role in the adaptive immune resistance of established GBM in response to antitumor active vaccination and provide us with a rationale for the clinical translation of this combination therapy.


PROVIDER: S-EPMC4951098 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5464463 | BioStudies
2020-01-01 | S-EPMC7523441 | BioStudies
2018-01-01 | S-EPMC5992384 | BioStudies
2019-01-01 | S-EPMC6796942 | BioStudies
2019-01-01 | S-EPMC6476322 | BioStudies
2019-01-01 | S-EPMC6287793 | BioStudies
2019-01-01 | S-EPMC6650357 | BioStudies
2019-01-01 | S-EPMC6694698 | BioStudies
2020-01-01 | S-EPMC7073290 | BioStudies
2019-01-01 | S-EPMC6422384 | BioStudies